<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34704111</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1433-0407</ISSN><JournalIssue CitedMedium="Internet"><Volume>92</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Der Nervenarzt</Title><ISOAbbreviation>Nervenarzt</ISOAbbreviation></Journal><ArticleTitle>[Amyotrophic lateral sclerosis and frontotemporal dementia-On the way to common gene-specific treatment approaches].</ArticleTitle><Pagination><StartPage>1219</StartPage><EndPage>1226</EndPage><MedlinePgn>1219-1226</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00115-021-01209-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) share common neuropathological features and in the case of a gene mutation, also a&#xa0;genetic cause. To date five ALS-FTD genes are described in the literature in addition to other rare variants.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The current state of research on treatment options for ALS and FTD is presented and an outlook on possible gene-specific approaches for ALS-FTD is provided.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">Analysis of the progression of ALS and FTD research by considering the increasing state of knowledge on the underlying pathomechanisms of the diseases.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In addition to anti-inflammatory approaches and stabilization of protein folding, promising gene-specific treatment approaches are currently being developed, which target common causes of ALS and FTD and therefore have an effect on both diseases.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">So far there are no causal treatment options for ALS and FTD. The increasing importance of genetic causes directs the focus to the development of gene-specific treatment.</AbstractText><CopyrightInformation>&#xa9; 2021. Springer Medizin Verlag GmbH, ein Teil von Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Anderl-Straub</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r Neurologie, RKU, Universit&#xe4;t Ulm, Oberer Eselsberg&#xa0;45, 89081, Ulm, Deutschland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuster</LastName><ForeName>Joachim</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r Neurologie, RKU, Universit&#xe4;t Ulm, Oberer Eselsberg&#xa0;45, 89081, Ulm, Deutschland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dorst</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r Neurologie, RKU, Universit&#xe4;t Ulm, Oberer Eselsberg&#xa0;45, 89081, Ulm, Deutschland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludolph</LastName><ForeName>Albert C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r Neurologie, RKU, Universit&#xe4;t Ulm, Oberer Eselsberg&#xa0;45, 89081, Ulm, Deutschland. albert.ludolph@rku.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Amyotrophe Lateralsklerose und frontotemporale Demenz&#xa0;&#x2013; auf dem Weg zu gemeinsamen genspezifischen Therapieans&#xe4;tzen.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Nervenarzt</MedlineTA><NlmUniqueID>0400773</NlmUniqueID><ISSNLinking>0028-2804</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="ger"><AbstractText Label="ZUSAMMENFASSUNG" NlmCategory="UNASSIGNED">HINTERGRUND: Die amyotrophe Lateralsklerose (ALS) und die frontotemporale Demenz (FTD) teilen gemeinsame neuropathologische und &#x2013;&#xa0;im Falle einer vorliegenden Genmutation&#xa0;&#x2013; auch genetische Ursachen. In der Literatur werden derzeit, neben weiteren selteneren Varianten, 5&#xa0;ALS-FTD-Gene beschrieben.</AbstractText><AbstractText Label="ZIEL DER ARBEIT" NlmCategory="UNASSIGNED">Der aktuelle Forschungsstand zu Therapiem&#xf6;glichkeiten der ALS und FTD soll dargestellt sowie ein Ausblick auf m&#xf6;gliche Gentherapien f&#xfc;r ALS-FTD gegeben werden.</AbstractText><AbstractText Label="MATERIAL UND METHODEN" NlmCategory="METHODS">Analyse des Zeitverlaufs der ALS- und FTD-Forschung unter Ber&#xfc;cksichtigung des steigenden Kenntnisstands der den Erkrankungen zugrunde liegenden Pathomechanismen.</AbstractText><AbstractText Label="ERGEBNISSE" NlmCategory="UNASSIGNED">Neben antiinflammatorischen Ans&#xe4;tzen oder der Stabilisierung von Proteinfaltungen werden aktuell vielversprechende genspezifische Therapieans&#xe4;tze entwickelt, welche auf gemeinsame Ursachen von ALS und FTD gerichtet sind und somit auch auf beide Erkrankungen wirken sollen.</AbstractText><AbstractText Label="DISKUSSION" NlmCategory="CONCLUSIONS">Bisher gibt es keine kausalen Therapiem&#xf6;glichkeiten f&#xfc;r ALS und FTD. Die steigende Bedeutung genetischer Ursachen lenkt den Fokus auf die Entwicklung genspezifischer Therapien.</AbstractText><CopyrightInformation>&#xa9; 2021. Springer Medizin Verlag GmbH, ein Teil von Springer Nature.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anti-inflammatory treatment</Keyword><Keyword MajorTopicYN="N">C9orf72</Keyword><Keyword MajorTopicYN="N">Gene therapy</Keyword><Keyword MajorTopicYN="N">Pathomechanism</Keyword><Keyword MajorTopicYN="N">Protein folding</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>27</Day><Hour>7</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34704111</ArticleId><ArticleId IdType="doi">10.1007/s00115-021-01209-7</ArticleId><ArticleId IdType="pii">10.1007/s00115-021-01209-7</ArticleId></ArticleIdList><ReferenceList><Title>Literatur</Title><Reference><Citation>Uenal&#xa0;H et&#xa0;al (2014) Plos One 9:4. https://doi.org/10.1371/journal.pone.0093932</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0093932</ArticleId></ArticleIdList></Reference><Reference><Citation>A. Al-Chalabi, A. Jones, C. Troakes, A. King, S. Al-Sarraj, and L. H. Van Den Berg, &#x201c;The genetics and neuropathology of amyotrophic lateral sclerosis,&#x201d; Acta Neuropathol., vol. 124, no. 3, pp. 339&#x2013;352, 2012, https://doi.org/10.1007/s00401-012-1022-4 .</Citation></Reference><Reference><Citation>K. Rascovsky et&#xa0;al., &#x201c;Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia,&#x201d; Brain, vol. 134, no. 9, pp.&#xa0;2456&#x2013;2477, 2011, https://doi.org/10.1093/brain/awr179 .</Citation></Reference><Reference><Citation>M. L. Gorno-Tempini et&#xa0;al., &#x201c;Classification of primary progressive aphasia and its variants,&#x201d; Neurology, vol. 76, no. 11, pp. 1006&#x2013;1014, 2011, https://doi.org/10.1212/WNL.0b013e31821103e6 .</Citation></Reference><Reference><Citation>Woollacott&#xa0;IOC, Rohrer&#xa0;JD (2016) The clinical spectrum of sporadic and familial forms of frontotemporal dementia. J&#xa0;Neurochem 138:6&#x2013;31. https://doi.org/10.1111/jnc.13654</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13654</ArticleId><ArticleId IdType="pubmed">27144467</ArticleId></ArticleIdList></Reference><Reference><Citation>A. H&#xfc;bers, A. C. Ludolph, A. Rosenbohm, E. H. Pinkhardt, J. H. Weishaupt, and J. Dorst, &#x201c;Amyotrophe Lateralsklerose: Eine Multisystemdegeneration,&#x201d; Nervenarzt, vol. 87, no. 2, pp.&#xa0;179&#x2013;188, 2016, https://doi.org/10.1007/s00115-015-0030-8 .</Citation></Reference><Reference><Citation>A. Montuschi et&#xa0;al., &#x201c;Cognitive correlates in amyotrophic lateral sclerosis: A population-based study in Italy,&#x201d; J. Neurol. Neurosurg. Psychiatry, vol. 86, no. 2, pp. 168&#x2013;173, 2015, https://doi.org/10.1136/jnnp-2013-307223 .</Citation></Reference><Reference><Citation>R. H. Tan et&#xa0;al., &#x201c;The underacknowledged PPA-ALS: A unique clinicopathologic subtype with strong heritability,&#x201d; Neurology, vol. 92, no. 12, pp. E1354&#x2013;E1366, 2019, https://doi.org/10.1212/WNL.0000000000007146 .</Citation></Reference><Reference><Citation>J. R. Burrell, M. C. Kiernan, S. Vucic, and J. R. Hodges, &#x201c;Motor Neuron dysfunction in frontotemporal dementia,&#x201d; Brain, vol. 134, no. 9, pp.&#xa0;2582&#x2013;2594, 2011, https://doi.org/10.1093/brain/awr195 .</Citation></Reference><Reference><Citation>D. Brenner and J. H. Weishaupt, &#x201c;Update on amyotrophic lateral sclerosis genetics,&#x201d; Curr. Opin. Neurol., vol. 32, no. 5, pp.&#xa0;735&#x2013;739, 2019, https://doi.org/10.1097/WCO.0000000000000737 .</Citation></Reference><Reference><Citation>D. W. Sirkis, E.&#x202f;G. Geier, L. W. Bonham, C. M. Karch, and J. S. Yokoyama, &#x201c;Recent advances in the genetics of frontotemporal dementia,&#x201d; Curr. Genet Med Rep., vol. 7, no. 1, pp.&#xa0;41&#x2013;52, 2019.</Citation></Reference><Reference><Citation>R. Ranganathan, S. Haque, K. Coley, S. Shepheard, J. Cooper-Knock, and J. Kirby, &#x201c;Multifaceted Genes in Amyotrophic Lateral Sclerosis-Frontotemporal Dementia,&#x201d; Front. Neurosci., vol. 14, no. July, pp. 1&#x2013;21, 2020, https://doi.org/10.3389/fnins.2020.00684 .</Citation></Reference><Reference><Citation>Gitler&#xa0;AD, Tsuiji&#xa0;H (2016) There has been an awakening: Emerging mechanisms of C9orf72 mutations in FTD/ALS. Brain Res 1647:19&#x2013;29. https://doi.org/10.1016/j.brainres.2016.04.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2016.04.004</ArticleId><ArticleId IdType="pubmed">27059391</ArticleId><ArticleId IdType="pmc">5003651</ArticleId></ArticleIdList></Reference><Reference><Citation>K. M&#xfc;ller et&#xa0;al., &#x201c;Comprehensive analysis of the mutation spectrum in 301 German ALS families,&#x201d; J. Neurol. Neurosurg. Psychiatry, vol. 89, no. 8, pp.&#xa0;817&#x2013;827, 2018, https://doi.org/10.1136/jnnp-2017-317611 .</Citation></Reference><Reference><Citation>G. Bensimon, L. Lacomblez, V. Meininger, and and the A. study Group, &#x201c;A controlled trial of RILUZOLE in amyotrophic lateral sclerosis,&#x201d; N. Engl. J. Med., vol. 330, no. 3, pp.&#xa0;153&#x2013;158, 1994.</Citation></Reference><Reference><Citation>J. C. Desport, P. M. Preux, T. C. Truong, J. M. Vallat, D. Sautereau, and P. Couratier, &#x201c;Nutritional status is a&#xa0;prognostic factor for survival in ALS patients,&#x201d; Neurology, vol. 53, no. 5, pp.&#xa0;1059&#x2013;1063, 1999, doi: 10.1212/wnl.53. Mai 1059.</Citation></Reference><Reference><Citation>J. C. Desport et&#xa0;al., &#x201c;Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis,&#x201d; Am. J. Clin. Nutr., vol. 74, no. 3, pp.&#xa0;328&#x2013;334, 2001, https://doi.org/10.1093/ajcn/74.3.328 .</Citation></Reference><Reference><Citation>A. C. Ludolph et&#xa0;al., &#x201c;Effect of High-Caloric Nutrition on Survival in Amyotrophic Lateral Sclerosis,&#x201d; Ann. Neurol., vol. 87, no. 2, pp. 206&#x2013;216, 2020, https://doi.org/10.1002/ana.25661 .</Citation></Reference><Reference><Citation>J. Dorst et&#xa0;al., &#x201c;Effect of high-caloric nutrition on serum neurofilament light chain levels in amyotrophic lateral sclerosis,&#x201d; J. Neurol. Neurosurg. Psychiatry, vol. 91, no. 9, pp. 1007&#x2013;1009, 2020, https://doi.org/10.1136/jnnp-2020-323372 .</Citation></Reference><Reference><Citation>J. Dorst et&#xa0;al., &#x201c;Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: a&#xa0;prospective observational study,&#x201d; J. Neurol., vol. 262, no. 4, pp.&#xa0;849&#x2013;858, 2015, https://doi.org/10.1007/s00415-015-7646-2 .</Citation></Reference><Reference><Citation>J. Dorst, G. Behrendt, and A. C. Ludolph, &#x201c;Non-invasive ventilation and hypercapnia-associated symptoms in amyotrophic lateral sclerosis,&#x201d; Acta Neurol. Scand., vol. 139, no. 2, pp. 128&#x2013;134, 2019, https://doi.org/10.1111/ane.13043 .</Citation></Reference><Reference><Citation>S. C. Bourke, M. Tomlinson, T. L. Williams, R. E. Bullock, P. J. Shaw, and G. J. Gibson, &#x201c;Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: A randomised controlled trial,&#x201d; Lancet Neurol., vol. 5, no. 2, pp. 140&#x2013;147, 2006, https://doi.org/10.1016/S1474-4422(05)70326-4 .</Citation></Reference><Reference><Citation>R. M. Tsai and A. L. Boxer, &#x201c;Therapy and clinical trials in frontotemporal dementia: past, present, and future,&#x201d; J Neurochem, vol. 138, no. 1, pp.&#xa0;211&#x2013;221, 2016, https://doi.org/10.1111/jnc.13640 .</Citation></Reference><Reference><Citation>R. Moretti, P. Torre, R. M. Antonello, G. Cazzato, and A. Bava, &#x201c;Frontotemporal dementia: Paroxetine as a&#xa0;possible treatment of behavior symptoms: A randomized, controlled, open 14-month study,&#x201d; Eur. Neurol., vol. 49, no. 1, pp. 13&#x2013;19, 2003, https://doi.org/10.1159/000067021 .</Citation></Reference><Reference><Citation>E. D. Huey, K. T. Putnam, and J. Grafman, &#x201c;A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia,&#x201d; Neurology, vol. 66, no. 1, pp.&#xa0;17&#x2013;22, 2015, https://doi.org/10.1212/01.wnl.0000191304.55196.4d .</Citation></Reference><Reference><Citation>H. Mitsumoto, B. R. Brooks, and V. Silani, &#x201c;Clinical trials in amyotrophic lateral sclerosis: Why so many negative trials and how can trials be improved?,&#x201d; Lancet Neurol., vol. 13, no. 11, pp.&#xa0;1127&#x2013;1138, 2014, https://doi.org/10.1016/S1474-4422(14)70129-2 .</Citation></Reference><Reference><Citation>K. Abe et&#xa0;al., &#x201c;Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a&#xa0;randomised, double-blind, placebo-controlled trial,&#x201d; Lancet Neurol., vol. 16, no. 7, pp. 505&#x2013;512, 2017, https://doi.org/10.1016/S1474-4422(17)30115-1 .</Citation></Reference><Reference><Citation>A. C. Ludolph et&#xa0;al., &#x201c;Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a&#xa0;randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial,&#x201d; Lancet Neurol., vol. 17, no. 8, pp. 681&#x2013;688, 2018, https://doi.org/10.1016/S1474-4422(18)30176-5 .</Citation></Reference><Reference><Citation>J. M. Statland et&#xa0;al., &#x201c;Rasagiline for Amyotrophic Lateral Sclerosis: a&#xa0;Randomized Controlled Trial,&#x201d; Muscle Nerve, vol. 59, no. 2, pp.&#xa0;201&#x2013;207, 2019, https://doi.org/10.1002/mus.26335.Rasagiline .</Citation></Reference><Reference><Citation>S. Paganoni et&#xa0;al., &#x201c;Trial of Sodium Phenylbutyrate&#x2013;Taurursodiol for Amyotrophic Lateral Sclerosis,&#x201d; N. Engl. J. Med., vol. 383, no. 10, pp.&#xa0;919&#x2013;930, 2020, https://doi.org/10.1056/nejmoa1916945 .</Citation></Reference><Reference><Citation>M. Otto et&#xa0;al., &#x201c;Konsortium zur Erforschung der frontotemporalen Lob&#xe4;rdegeneration,&#x201d; Nervenarzt, vol. 82, no. 8, pp.&#xa0;1002&#x2013;1005, 2011, https://doi.org/10.1007/s00115-011-3261-3 .</Citation></Reference><Reference><Citation>P. Novak et&#xa0;al., &#x201c;AADvac1, an Active Immunotherapy for Alzheimer&#x2019;s Disease and Non Alzheimer Tauopathies: An Overview of Preclinical and Clinical Development,&#x201d; J. Prev. Alzheimer&#x2019;s Dis., vol. 6, pp.&#xa0;63&#x2013;69, 2019, https://doi.org/10.14283/jpad.2018.45 .</Citation></Reference><Reference><Citation>T. Miller et&#xa0;al., &#x201c;Phase 1&#x2013;2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS ,&#x201d; N. Engl. J. Med., vol. 383, no. 2, pp.&#xa0;109&#x2013;119, 2020, https://doi.org/10.1056/nejmoa2003715 .</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>